Precision therapy guided by genotypic antibiotic resistance for Helicobacter pylori eradication: A prospective, randomized controlled trial

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 42

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Gastroenterol. Nov 14, 2025; 31(42): 110717
Published online Nov 14, 2025. doi: 10.3748/wjg.v31.i42.110717

Table 5 Helicobacter pylori resistance rate, n (%)

Antibiotics	Susceptible	Resistant
Clarithromycin	60 (61.9)	37 (38.1)
Levofloxacin	58 (59.8)	39 (40.2)
Clarithromycin and levofloxacin	38 (39.2)	17 (17.5)

Citation: Xu Y, Hao JW, Min CC, Yang L, Ma CP, Shi C, Mao T, Tian ZB, Wang T, Yu YN. Precision therapy guided by genotypic antibiotic resistance for Helicobacter pylori eradication: A prospective, randomized controlled trial. World J Gastroenterol 2025; 31(42): 110717
URL: https://www.wjgnet.com/1007-9327/full/v31/i42/110717.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i42.110717

Xu Y, Hao JW, Min CC, Yang L, Ma CP, Shi C, Mao T, Tian ZB, Wang T, Yu YN. Precision therapy guided by genotypic antibiotic resistance for Helicobacter pylori eradication: A prospective, randomized controlled trial. World J Gastroenterol 2025; 31(42): 110717 [PMID: 41278167 DOI: 10.3748/wjg.v31.i42.110717]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.